Mktman2024
2 years ago
The proper company name associated with CMPX symbol
Compass Therapeutics . If one were to review the 6 or 7 bispecifics currently approved for cancer, the efficacy of CTX 009 , CTX 471 and CTX 8371 in early trials is astounding...with a very unique Moa...still not understood by most analysts. It clearly warrants a collaboration with Merck on 471 and potentially many others. The stitchmab they have developed is a real game changing technology optimizing the best suitable mab combinations , along with Taxol, Keytruda and others ...supercharging the efficacy of current drug therapies. This stock has multiple undervalued assets.